Dr. Reddy's Semaglutide launch for Type 2 Diabetes in India.
Dr. Reddy’s Laboratories has launched Obeda, a generic semaglutide injection for Type 2 diabetes, marking it as the first Indian company to receive Drug Controller General of India (DCGI) approval for this glucagon-like peptide-1 (GLP-1) receptor agonist. The launch introduces a more accessible treatment option for managing Type 2 diabetes in India.
Obeda, available in 2mg and 4mg strengths, is administered as a once-weekly subcutaneous injection. The drug’s approval was based on Phase III studies demonstrating non-inferior efficacy and a safety profile comparable to existing treatments. This development provides a cost-effective alternative for patients requiring semaglutide, a widely used medication in diabetes management.
The introduction of Obeda follows the expiration of patents on innovator semaglutide products, enabling Dr. Reddy’s to offer a generic version. This launch is expected to increase access to this essential medicine, potentially benefiting a large population of diabetic patients across India. The availability of a locally manufactured semaglutide injection could also reduce healthcare costs associated with importing similar medications.
Dr. Reddy’s entry into the semaglutide market reflects a strategic move to capitalize on the growing demand for diabetes treatments, driven by increasing prevalence of the disease in India. The company’s ability to secure DCGI approval underscores its capabilities in developing and commercializing complex generic formulations.
About the Author
